Evidence map›Paper›PMID 36215506›Full record

ReviewProceedings of the National Academy of Sciences of the United States of America2022

Pandemic origins and a One Health approach to preparedness and prevention: Solutions based on SARS-CoV-2 and other RNA viruses.

Gerald T Keusch, John H Amuasi, Danielle E Anderson, Peter Daszak, Isabella Eckerle, Hume Field, Marion Koopmans, Sai Kit Lam, Carlos G Das Neves, Malik Peiris and 4 more

Abstract readReview
In one paragraph

Review in Proceedings of the National Academy of Sciences of the United States of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Spike destabilization attenuates Mink Cluster 5 SARS-CoV-2.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Gerald T KeuschDepartment of Medicine, Section of Infectious Diseases, National Emerging Infectious Diseases Laboratories, Center for Emerging Infectious Diseases Policy and Research, Boston University, Boston, MA 02215.
John H AmuasiSchool of Public Health, Department of Global Health, Kwame Nkrumah University of Science and Technology (KNUST), PMB UPO, Kumasi 00000 Ghana.
Danielle E AndersonVictorian Infectious Diseases Reference Laboratory, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, 3000 Australia.ORCID 0000-0003-4791-5024
Peter DaszakEcoHealth Alliance, New York, NY 10018.ORCID 0000-0002-2046-5695
Isabella EckerleGeneva Centre for Emerging Viral Diseases, Laboratory of Virology, Division of Infectious Diseases, University Hospital of Geneva, CH-1205 Geneva, Switzerland.
Hume FieldEcoHealth Alliance, New York, NY 10018.ORCID 0000-0002-4671-7002
Marion KoopmansDepartment of Viroscience and Pandemic and Disaster Preparedness Centre, Erasmus Medical Center, CA 3000 Rotterdam, Netherlands.
Sai Kit LamUniversity of Malaya, 50603 Kuala Lumpur, Malaysia.ORCID 0000-0002-8611-7845
Carlos G Das NevesNorwegian Veterinary Institute, 1433 Ås, Norway.ORCID 0000-0003-0348-4808
Malik PeirisSchool of Public Health, The University of Hong Kong, 999077 Hong Kong SAR, China.ORCID 0000-0001-8217-5995
Stanley PerlmanDepartment of Microbiology and Immunology, Department of Pediatrics, University of Iowa, Iowa City, IA 52242.ORCID 0000-0003-4213-2354
Supaporn WacharapluesadeeThai Red Cross Emerging Infectious Diseases Clinical Center, King Chulalongkorn Memorial Hospital and Chulalongkorn University, Bangkok 10330, Thailand.ORCID 0000-0001-7636-1900
Su YadanaEcoHealth Alliance, New York, NY 10018.ORCID 0000-0003-0447-2083
Linda SaifCenter for Food Animal Health (CFAH), Ohio Agricultural Research and Development Center, Animal Sciences Department, College of Food, Agricultural and Environmental Sciences, Veterinary Preventive Medicine Department, College of Veterinary Medicine, The Ohio State University, Wooster, OH 44691.ORCID 0000-0002-3224-9009

Funding

SARS-CoV Proteins in Heterologous Viral InfectionP01AI060699 · NIAID · UNIVERSITY OF IOWA · PI PERLMAN, STANLEY · 2004 to 2021
$21.5M
Role of eicosanoids in pathogenic human CoV infectionsR01AI129269 · NIAID · UNIVERSITY OF IOWA · PI Stanley Perlman · 2016 to 2026
$4.7M
NIAID NIH HHS P01 AI060699NIAID NIH HHS R01 AI129269
6 · The paper itself

Abstract

COVID-19 is the latest zoonotic RNA virus epidemic of concern. Learning how it began and spread will help to determine how to reduce the risk of future events. We review major RNA virus outbreaks since 1967 to identify common features and opportunities to prevent emergence, including ancestral viral origins in birds, bats, and other mammals; animal reservoirs and intermediate hosts; and pathways for zoonotic spillover and community spread, leading to local, regional, or international outbreaks. The increasing scientific evidence concerning the origins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is most consistent with a zoonotic origin and a spillover pathway from wildlife to people via wildlife farming and the wildlife trade. We apply what we know about these outbreaks to identify relevant, feasible, and implementable interventions. We identify three primary targets for pandemic prevention and preparedness: first, smart surveillance coupled with epidemiological risk assessment across wildlife-livestock-human (One Health) spillover interfaces; second, research to enhance pandemic preparedness and expedite development of vaccines and therapeutics; and third, strategies to reduce underlying drivers of spillover risk and spread and reduce the influence of misinformation. For all three, continued efforts to improve and integrate biosafety and biosecurity with the implementation of a One Health approach are essential. We discuss new models to address the challenges of creating an inclusive and effective governance structure, with the necessary stable funding for cross-disciplinary collaborative research. Finally, we offer recommendations for feasible actions to close the knowledge gaps across the One Health continuum and improve preparedness and response in the future.

Indexed as

ChiropteraCOVID-19One HealthAnimalsAnimals, WildHumansPandemicsSARS-CoV-2ZoonosesCOVID-19 origins and spreadDrivers of emerging infectious diseasesOne Health solutionspandemic preparednessspillover and spillback

Identifiers

PMID36215506
PMCPMC9586299

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.